The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 6 of the 20 sources its claims cite were checked for support.
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Open accessAbstract
This Position Statement has been endorsed by the International Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The International Society for Sexual Medicine...
Overview
CoChat Summary
TL;DR
This global consensus position statement concludes that the only evidence-based indication for testosterone therapy in women is treatment of postmenopausal women with hypoactive sexual desire disorder (HSDD) after formal biopsychosocial assessment. It finds insufficient evidence for testosterone use for any other symptom, condition, or disease prevention, and recommends only formulations achieving premenopausal physiologic testosterone concentrations with monitoring.
Key findings
- The only evidence-based indication is HSDD in postmenopausal women; meta-analyses show a beneficial effect on sexual function including an average of one satisfying sexual event per month and increases in sexual desire, arousal, orgasmic function, pleasure, and sexual responsiveness, with reduced sexual concerns/distress (Level I, Grade A). There are insufficient data for premenopausal women or for any other outcome.
- No effect was found on general wellbeing (Level I, Grade A), depressed mood (Level I, Grade B), bone mineral density at the spine, total hip, or femoral neck at 12 months (Level I, Grade A), or lean body mass, total body fat, or muscle strength (Level I, Grade A); evidence is insufficient for cognitive performance.
- Safety findings: mild increases in acne and body/facial hair growth but not alopecia, clitoromegaly, or voice change (Level I, Grade A); oral testosterone adversely affects HDL- and LDL-cholesterol and is not recommended; non-oral short-term therapy shows no significant adverse lipid effects; no increases in blood pressure, blood glucose, or HbA1c; a non-significant trend for increased VTE; no serious adverse events, but safety data are not available beyond 24 months.
- Breast findings: testosterone does not increase mammographic breast density; short-term transdermal testosterone does not impact breast cancer risk; data are insufficient for long-term breast cancer risk or prevention. Systemic DHEA is not recommended for HSDD.
Methods
- A Task Force of representatives from leading societies conducted a systematic review and meta-analysis of the benefits and risks of testosterone therapy for women, then met on 17 May 2019 in Berlin, Germany, and drafted this consensus position statement.
- Recommendations regarding benefits and risks are based on blinded placebo/comparator RCTs of at least 12 weeks’ duration included in meta-analyses; findings are reported with Levels of Evidence and Grades of Recommendation, and clinical practice recommendations are agreed expert opinions reached by unanimous consensus.
Limitations
- The paper states insufficient data for premenopausal women; recommendations cannot be generalized to other FSD subtypes or women without sexual dysfunction; and they do not apply to injectables, pellets, formulations producing supraphysiological testosterone concentrations, or compounded preparations.
- The paper states RCTs excluded women at high cardiometabolic disease risk, most included women taking concurrent estrogen therapy, and all were of relatively short duration; safety data for physiologic doses are not available beyond 24 months; long-term breast cancer risk and effects on myocardial infarction or death are insufficient.
- The paper states few musculoskeletal studies, small participant numbers, all participants on concurrent estrogen, and none in women with osteoporosis; also evident from the text, many recommendations are Expert Opinion rather than RCT-based, and no approved female testosterone product exists, requiring off-label use of male formulations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 6 Not valid · 7 Not checked · 36 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“as evidence that ' free ' testosterone is the biologically active testosterone fraction is lacking 9 (Expert Opinion).”
What the sources say
- Disputedcites [9] sourceExperimental — accuracy not yet measured
In “What is the Biologically Active Fraction of Circulating Testosterone?” (page unavailable), the paper explicitly describes experimental support for the free hormone hypothesis and clinical findings that support it. It treats the hypothesis as debated, but does not say evidence for it is lacking. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Testosterone concentrations decline during the reproductive years 3,4 (Level IIB).”
What the sources say
- Not checked — no full text of the sourcecites [3] source
- Supportedcites [4] source
Table 3 shows that the total-testosterone reference range shifts downward across the reproductive-age groups: 20–29, 30–39, and 40–49 years. The Results also report an age-related decline in testosterone, although the study’s overall analysis spans ages 20–80. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Testosterone concentrations appear to be maintained in women beyond the age of 65 years, but whether this confers a benefit is yet to be understood 3,5 (Level IIB).”
What the sources say
- Not checked — no full text of the sourcecites [3] source
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Results (p. 1) report that free testosterone did not vary by age in women aged 65–98, supporting the claim for free testosterone. But total testosterone declined until age 80, so testosterone concentrations generally cannot be described as maintained throughout this age range. The Discussion (p. 7) also says that the benefits of testosterone in late postmenopausal women remain unclear. (LLM, conf=0.90)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Total testosterone can be measured with high accuracy and reproducibility using liquid/gas chromatography and tandem mass spectrometry assays (LC/GC-MS/MS) 6 (Grade B).”
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The LC-MSMS section (p. 3) reports accuracy, precision, and between-day reproducibility for total serum testosterone measurements, supporting the liquid-chromatography part of the claim. The paper does not establish the same performance for gas chromatography–tandem mass spectrometry; its mentions of GC-MS do not describe a GC-MS/MS assay evaluated in this study. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Direct assays for the measurement of total and free testosterone are highly unreliable in the female range 6,7 (Grade A).”
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Discussion (p. 9) says the tested total-testosterone immunoassays lack adequate accuracy and precision for serum measurements in normal females. It says this has implications for free-testosterone determinations, but the study did not directly evaluate free-testosterone assays, so the claim about those assays is not established by this source. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [7] source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
35 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 7
- Probably not a substantial claim. 10
Citations
Cites
Androgen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy
Davison, S. L., Bell, R., Donath, S., Montalto, J. G., & Davis, S. R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0212 · Cited by 998 · cited 1×
“(3) Recommendations pertaining to the associations between endogenous androgen concentrations and female sexual function”
Self-citationWang, C., Catlin, D. H., Demers, L. M., Starcevic, B., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031287 · Cited by 580 · cited 3×
“(e) Direct assays for the measurement of total and free testosterone are highly unreliable in the female range (6, 7) (Grade A).”
InfluentialCirculating Androgen Levels and Self-reported Sexual Function in Women
Davis, S. R. (2005) · JAMA · doi:10.1001/jama.294.1.91 · Cited by 510
Self-citationA Reappraisal of Testosterone’s Binding in Circulation: Physiological and Clinical Implications
Goldman, A. L., Bhasin, S., Wu, F. C. W., Krishna, M., Matsumoto, A. M., & Jasuja, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00025 · Cited by 414 · cited 1×
“h Current research into testosterone physiology and clinical effects should mainly focus on measuring total testosterone as the main biomarker rather than “free” testosterone, as evidence that ‘free testosterone’ is the biologically active testosterone fraction is lacking [9] (Expert Opinion).”
BackgroundIslam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30189-5 · Cited by 278
Self-citationToward Excellence in Testosterone Testing: A Consensus Statement
Rosner, W., & Vesper, H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1314 · Cited by 248 · cited 2×
“f Reference laboratories should be “harmonized” with biological standards in co-ordination with the Center for Disease Control [8] (Expert Opinion).”
BackgroundClayton, A. H., Goldstein, I., Kim, N. N., Althof, S. E., Faubion, S. S., Faught, B. M., Parish, S. J., Simon, J. A., Vignozzi, L., Christiansen, K., et al. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.11.002 · Cited by 226
Self-citationToward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions—Part II
Parish, S. J., Goldstein, A. T., Goldstein, S. W., Goldstein, I., Pfaus, J., Clayton, A. H., Giraldi, A., Simon, J. A., Althof, S. E., Bachmann, G., et al. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.09.020 · Cited by 191 · cited 2×
“d The diagnosis of HSDD in clinical practice should be based on thorough clinical assessment [11] guided by available diagnostic criteria such as ISSWSH [12,13] or the International Classification of Diseases 11th Edition [14] (Expert Opinion).”
MethodSelf-citationHaring, R., Hannemann, A., John, U., Radke, D., Nauck, M., Wallaschofski, H., Owen, L., Adaway, J., Keevil, B. G., & Brabant, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2134 · Cited by 185 · cited 1×
“(4) Recommendations regarding testosterone treatment of naturally or surgically postmenopausal women with HSDD, with/or without concurrent estrogen therapy (a) Testosterone therapy, in doses that approximate physiological testosterone concentrations for premenopausal women, exerts a beneficial effect on sexual functio…”
BackgroundDeveloping clinical guidelines
Shekelle, P. G., Woolf, S. H., Eccles, M., & Grimshaw, J. (1999) · PubMed Central · doi:10.25405/ncl.34593798 · Cited by 170
Research works printed but not linked: 1
- Shekelle PG, 1999, West J Med, 170, 348
Cited by
Premature ovarian insufficiency: an international menopause society white paper
Panay, N., Anderson, R. A., Nappi, R. E., Vincent, A. J., Vujovic, S., Webber, L., & Wolfman, W. (2020) · Climacteric · doi:10.1080/13697137.2020.1804547 · Cited by 297
Self-citationMenopause—Biology, consequences, supportive care, and therapeutic options
Davis, S. R., Pinkerton, J., Santoro, N., & Simoncini, T. (2023) · Cell · doi:10.1016/j.cell.2023.08.016 · Cited by 233
Self-citationHamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020) · Post Reproductive Health · doi:10.1177/2053369120957514 · Cited by 192
Self-citationParish, S. J., Simon, J. A., Davis, S. R., Giraldi, A. G. E., Goldstein, I., Goldstein, S. W., Kim, N. N., Kingsberg, S. A., Morgentaler, A., Nappi, R. E., et al. (2021) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.10.009 · Cited by 178
Self-citationClinical Effects of Early or Surgical Menopause
Kingsberg, S. A., Larkin, L. C., & LIU, J. H. (2020) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003729 · Cited by 168
Self-citation
Metadata
- Authors
- Davis, S. R., Baber, R., Panay, N., Bitzer, J., Cerdas Perez, S., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I., Liu, J., Parish, S. J., Pinkerton, J., Rymer, J., Simon, J. A., Vignozzi, L., & Wierman, M. E.
- Affiliations
- Monash University (AU)
- University of Sydney, Sydney, Australia;
- Queen Charlotte's and Chelsea Hospital (GB)
- International AIDS Society (CH)
- Endocrinology Department, Hospital Cima and University of Costa Rica, San José, Costa Rica;
- University of Florida (US)
- University Hospitals of Cleveland (US)
- National and Kapodistrian University of Athens (GR)
- Weill Cornell Medicine (US)
- University of Virginia Health System (US)
- Royal College of Obstetricians and Gynaecologists (GB)
- George Washington University (US)
- Endocrine Society (US)
- Corresponding author
- Davis, Susan R.
- Venue
- Climacteric
- Publisher
- Informa UK Limited
- Published
- 2019-09-02
- Volume
- 22
- Issue
- 5
- Pages
- 429-434
- ISSN
- 1369-7137 (ISSN-L)
- 1473-0804
- OpenAlex
- W2971483732
- Semantic Scholar
- 567daafa1babc04cb5efb5c62e069224928c0852
- Cited by
- 113
- References
- 18
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 17 · 2023: 15 · 2022: 9 · 2021: 20 · 2020: 14
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-10-15)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Climacteric (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (acceptedVersion, cc-by-nc-nd)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Keywords
- testosterone replacement therapy, women, menopause, andropause, hormone replacement therapy, consensus statement, Endocrine Society
- MeSH terms
- Female, Humans, Societies, Medical, Testosterone, Global Health, Randomized Controlled Trials as Topic, Women's Health, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global Consensus Position Statement on the Use of Testosterone Therapy for Women. https://app.cochat.ai/papers/10.1080/13697137.2019.1637079
- The paper
- Davis, S. R., Baber, R., Panay, N., Bitzer, J., Cerdas Perez, S., Islam, R. M., Kaunitz, A. M., Kingsberg, S. A., Lambrinoudaki, I., Liu, J., Parish, S. J., Pinkerton, J., Rymer, J., Simon, J. A., Vignozzi, L., & Wierman, M. E. (2019). Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. https://doi.org/10.1080/13697137.2019.1637079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
